Lexicon Completes Phase I Clinical Trial of LX1033

Lexicon now plans to move LX1033 forward into a Phase II study in patients with diarrhoea-predominant irritable bowel syndrome.

Lexicon Pharmaceuticals, a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced last week it has completed a Phase I clinical trial of LX1033, an orally-delivered small molecule drug candidate for the treatment of diarrhoea-predominant irritable bowel syndrome.

LX1033 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation without affecting serotonin levels in the brain.

Study endpoints included safety and tolerability together with pharmacokinetic and pharmacodynamic parameters consisting of measures of both plasma and urinary 5-hydroxyindoleacetic acid biomarker.

The trial involv